Kupando Raises €10M for Innate Immunity Cancer Therapies

German biotech firm Kupando has successfully bolstered its Series A funding round by an additional €10 million, bringing the total capital raised in this round to €23 million. This significant infusion of capital is earmarked to propel the company's innovative approach to cancer treatment, which draws inspiration from the robust immune defenses observed in the animal kingdom. The funding will primarily support the initiation of a Phase 1b clinical trial for their lead candidate, KUP101, targeting advanced solid tumors, and will also accelerate preclinical development in the infectious disease arena.

The latest investment tranche was spearheaded by existing investor Remiges Ventures, with co-leadership from LifeCare Partners. The round also saw continued backing from Brandenburg Kapital, High-Tech Gründerfonds, and Ventura Biomed Investors. Notably, Carma Fund has joined as a new strategic investor, signaling strong confidence in Kupando's scientific platform and future potential. This extension highlights a robust investor appetite for novel immuno-oncology and immune-modulating therapeutics within the European market.

Kupando is pioneering a novel therapeutic strategy centered on dual Toll-Like Receptor (TLR) agonists, specifically targeting TLR 4 and TLR 7. This approach aims to stimulate the innate immune system and induce a state of 'trained immunity,' a concept that mimics the lasting protective responses seen in animals relying solely on innate immunity. Their lead candidate, KUP101, is designed for systemic administration in solid tumors and holds promise for combating antimicrobial-resistant infections, a growing global health concern.

The company's founder and CEO, Johanna Holldack, MD, expressed gratitude for the sustained support, stating, "This additional funding is a testament to the potential of our innovative dual TLR agonist platform and will be instrumental in advancing KUP101 into clinical studies for solid tumors and accelerating our crucial work in infectious diseases." She emphasized the company's mission to harness the innate immune system for transformative patient therapies.

This funding round occurs amidst a dynamic European biotech landscape. Recent comparable funding activities include Exeliom Biosciences' €2.85 million raise for immunotherapies, Engitix securing €21 million for extracellular matrix-targeted treatments, and ErVimmune's €17 million for cancer vaccines. Within Germany, T-CURX raised €17.7 million for novel cancer cell therapies. Larger rounds, such as T-Therapeutics (€27.5 million), Highlight Therapeutics (€15 million), and Adcytherix (€105 million), further underscore investor confidence in platform-driven oncology approaches.

Martin Raditsch, PhD, Managing Partner at Carma Fund, commented on the new investment, "Kupando’s unique approach to leveraging innate immunity holds immense promise across oncology and infectious diseases. This successful funding round, especially in the current challenging financial climate, underscores the confidence we, as investors, have in Kupando’s science, team, and potential to deliver impactful solutions for unmet medical needs." The company, founded in 2018, is now poised to translate its promising preclinical data into tangible clinical outcomes.